Analyse Pluri Inc. (PLUR) — Kairos Score 45/100

À propos de Pluri Inc.

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Informations clés

🕴️ Activité des initiés (90 jours)

2 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Pluri Inc..

🏦 Hedge Funds

0 fonds institutionnels déclarent une position sur PLUR dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur PLUR.

• Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
• Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.